Robert J. Mather

Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.

Stephan Grissmer, A. N. Nguyen, Jayashree Aiyar et al. · Molecular Pharmacology · 1994 · 780 citations

Natural Sciences, Biophysics, Pharmacology +17

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Hans Rollema, Leslie K. Chambers, J.W. Coe et al. · Neuropharmacology · 2006 · 535 citations

Public Health, Pharmacology, Pharmacotherapy +14

Selective Inhibition of KCC2 Leads to Hyperexcitability and Epileptiform Discharges in Hippocampal Slices and<i>In Vivo</i>

Sudhir Sivakumaran, Ross A. Cardarelli, Jamie Maguire et al. · Journal of Neuroscience · 2015 · 105 citations · Full text

Life Sciences, Neuroscience, Pharmacology +16

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.

Angela Nguyen, John C. Kath, Douglas C. Hanson et al. · Molecular Pharmacology · 1996 · 101 citations

Medicine, Medicinal Chemistry, Pharmacology +7

Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

Christopher J. O’Donnell, Bruce N. Rogers, Brian S. Bronk et al. · Journal of Medicinal Chemistry · 2009 · 74 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17